The National Institute for Health and Care Excellence (Nice) rejected both donanemab and lecanemab, citing their minimal benefits and concerns about potential severe side effects like brain swelling.
Prof Rob Howard emphasizes the necessity to prioritize access to diagnostics and existing care options for Alzheimer’s patients rather than solely focusing on new drug approvals.
Alzheimer's Research UK highlights that about 130 drugs are currently under development, with a majority intended to delay, slow, or even reverse Alzheimer's disease.
Despite Nice's decisions, experts believe that ongoing research and future therapies may offer more effective treatments than those currently on the table.
[
Collection
]
[
|
...
]